Abstract:ABSTRACTIntroduction Precision medicine based on the driver genes mutation status is the current systemic therapeutic paradigm in patients with lung cancer. Next-generation sequencing (NGS) has emerged as a powerful platform for molecular diagnosis by virtue of high-throughput and massively parallel sequencing. Liquid biopsy also enabled the dynamic monitoring and comprehensive profiling of lung cancer in a noninvasive manner. However, challenges remain in the field of technology and clinical applications, especially in the era of immunotherapy.Areas covered Here, we update the role of NGS in the context of lung cancer screening, molecular diagnosis, predictive and prognostic biomarkers, and guiding personalized treatment.Expert opinion The NGS application for actable genomic alternation has greatly changed the therapeutic landscape in patients with lung cancer including perioperative setting and advanced stage. Meanwhile, emerging evidence has shown the potential of other applications such as early screening and detection, and MRD. However, challenges remain such as the lack of standardized protocols across different platforms and bioinformatics analysis pipelines, and the complexity of interpreting and leveraging numerous genomic mutation messages for therapy selection. Future research is needed to overcome these challenges and expand the applications of NGS to other aspects such as immunotherapy.KEYWORDS: Next-generation sequencing (NGS)precision medicinelung cancermolecular diagnosticsliquid biopsy Article highlights NGS is a powerful tool for identifying genomic alterations in lung cancer, providing a deep understanding of tumor biology and aiding clinical decision making.Liquid biopsy, a minimally invasive alternative to tissue biopsy, allows for the detection of tumor-derived genetic material in blood or other body fluids, enabling real-time monitoring of tumor progression or response to therapy.The use of NGS in liquid biopsy has revolutionized the field of lung cancer diagnosis and management, facilitating the identification of actionable mutations and the development of personalized treatment strategies.Challenges still exist in the implementation of NGS-based biopsy in clinical practice, including the need for standardized protocols, optimization of sequencing platforms, and interpretation of complex data, the clinical application of MRD detection, early diagnosis, and biomarkers for immunotherapy.Declaration of interestsThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis work was sponsored by grants from the National Natural Science Foundation of China (No. 82172869 and No. 81972167) and the Program of Shanghai Academic Research Leader (No. 21XD1423200).

Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types

Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy

Targeted Next-Generation Sequencing As a Comprehensive Test for Mendelian Diseases: a Cohort Diagnostic Study.

The Utilization of Next-Generation Sequencing to Detect Somatic Mutations and Predict Clinical Prognosis of Chinese Non-Small Cell Lung Cancer Patients

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Assessment of the Clinical Application of Detecting EGFR, KRAS, PIK3CA and BRAF Mutations in Patients with Non-Small Cell Lung Cancer Using Next-Generation Sequencing

An Accurate And Comprehensive Clinical Sequencing Assay For Cancer Targeted And Immunotherapies

Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in Nonsmall Cell Lung Cancer

Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing

Efficacy Comparison of Targeted Next-Generation Sequencing in the Identification of Somatic Mutations in Circulating Tumor DNA from Different Stages of Lung Cancer

Performance Validation of an Amplicon-Based Targeted Next-Generation Sequencing Assay and Mutation Profiling of 648 Chinese Colorectal Cancer Patients.

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology

Recent Advance of Next-Generation Sequencing in Patients with Lung Cancer

Oncogenic Alterations Reveal Key Strategies for Precision Oncology in Melanoma Treatment

Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy.

An Ultra-Deep Next Generation Sequencing Method for Cfdna Detection in Nsclc Patients.

Clinical Next Generation Sequencing for Precision Medicine in Cancer